Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Closed System Drug Transfer Devices to 2026

Published by Greystone Research Associates Product code 985625
Published Content info
Delivery time: 1-2 business days
Back to Top
Closed System Drug Transfer Devices to 2026
Published: February 2, 2021 Content info:

Technology-driven Patient & Caregiver Safety

The administration of drugs deemed hazardous to humans has been receiving increasing amounts of scrutiny in recent years as the dangers of these substances become more clearly understood. For caregivers and their patients, the therapeutic area that is at the forefront of attempts to mitigate exposure to cytotoxic drugs is clinical oncology, a field that - in spite of promising new drugs based on therapeutic antibodies - continues to rely heavily on antineoplastics, a class that includes alkylating agents and antimetabolites, to treat a wide range of cancers. Regulatory and industry efforts to create standards and procedures designed to protect workers and patients from accidental and incidental exposure to cytotoxics are being driven by data that suggests a causal link between exposure and health issues.

What You Will Learn:

  • What are the key segments and addressable markets that comprise the market for cytotoxic drug delivery?
  • What are the major therapeutic demand drivers for cytotoxic drug therapeutics?
  • What are the design factors and technologies that are being used in commercial and development-stage closed drug transfer systems?
  • What is the market share and product position in the market and what will it look like in 2026?
  • Who are the companies behind the current generation of cytotoxic transfer devices and what are their business models?
  • What is the role of pharma-device alliances and design partnerships in the commercialization and market access of new and emerging closed system drug transfer devices?
  • What is the impact of economic, technology, and regulatory factors on CSDT device demand?
Table of Contents
Product Code: CST929F

Table of Contents

  • Closed System Drug Transfer Devices to 2026
  • Executive Summary
  • Oncology Drug Trends
  • The Evolution in Oncology Therapeutics
  • Chemotherapy
  • Immunotherapy
  • The Evolving Role of Cytotoxic Drugs
  • The Recombinant Drug Ecosystem
  • CSTD Market Dynamics
  • Pharmacy
  • Point-of-Care
  • Technology Factors
  • CSDT Competitive Landscape
  • Risks and Opportunities
  • The Market for Cytotoxic Drugs
  • Evolving Prescribing Factors
  • Closed System Drug Transfer Design Factors
  • Oncology Therapeutics Medication Safety
  • Material Selection Issues
  • Drug Reconstitution
  • Oncology Drug Administration and Dosing
  • Drug-Specific Dosing Modification and Individualized Dosing
  • CSDT Device Performance Factors
  • Vapor Containment
  • Testing Protocols
  • CSDT Devices - Key Market Segments
  • Teaching Hospitals
  • Regional/Community Hospitals
  • Oncology Centers/Clinics
  • Closed Drug Transfer - Device Assessments
  • Market Assessments and Forecasts
  • Geographic Data
  • Company Profiles
Back to Top